连续脏置换治疗的败血休克患者中波萨可纳的血度:一个病例报告
Alternative therapies in health and medicine
|May 14, 2024
概括
连续脏替代疗法 (CRRT) 在重症患者中没有显著改变波萨可纳的血度. 这表明在CRRT期间可能不需要对Posaconazole剂量进行调整.
科学领域:
- 药理动力学 药理动力学
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
背景情况:
- 波萨可纳是一种用于重症患者的抗真菌药物.
- 持续置换疗法 (CRRT) 经常在重症监护室用于器官支持.
- 在重症患者中,CRRT对Posaconazole药理动学的影响尚未得到充分证实.
研究的目的:
- 评估CRRT对重症患者的波萨可纳血度的影响.
- 为了确定在CRRT期间是否需要Posaconazole剂量调整.
主要方法:
- 一个病例介绍了患有败血性休克,心脏骤停和多器官功能障碍综合征的重症患者.
- 波萨可纳被用于抗感染治疗.
- 在CRRT期间和之后测量了Posaconazole的血度 (低谷和高峰).
主要成果:
- 在CRRT的第7天和第11天,波萨可纳的最低度分别为1.9 mg/L和0.8 mg/L.
- 在CRRT的第7天和第11天,波萨可纳的峰值度分别为6.6 mg/L和4.3 mg/L.
- 停止CRRT后的度与CRRT期间相比没有显著差异;没有报告任何不良事件.
结论:
- 在CRRT期间和之后,波萨可纳的血度保持稳定.
- 目前的数据表明,在接受CRRT的重症患者中,可能不需要对Posaconazole剂量进行调整.
相关概念视频
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
371
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
371
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
414
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
414
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Continuous Renal Replacement Therapy
2.3K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.3K
Acute Kidney Injury III: Clinical Manifestations
1.8K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.8K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
559
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
559


